Quercetin Derivatives as Potential Therapeutic Agents: An Updated Perspective on the Treatment of Nicotine-Induced Non-Small Cell Lung Cancer

• Published in: International journal of molecular sciences Vol. 24; no. 20; p. 15208
• Main Author: Alsharairi, Naser A
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2023; MDPI
• Subjects: Amino acids; Apoptosis; Binding sites; Bioavailability; Bioflavonoids; Cancer; Carcinogens; Care and treatment; Cell adhesion & migration; Cell cycle; Cytotoxicity; Enzymes; Flavones; Flavonoids; flavonols; Fruits; Health aspects; Judaica; Kinases; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Metastasis; molecular mechanisms; Nanoparticles; Nicotine; non-small cell lung cancer; Oncology, Experimental; Polyphenols; Proteins; quercetin derivatives; Review; Substance abuse
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms242015208

Flavonoids are the largest group of polyphenols, represented by many compounds that exhibit high anticancer properties. Quercetin (Q) and its main derivatives (rutin, quercitrin, isoquercitrin, isorhamnetin, tamarixetin, rhamnetin, and hyperoside) in the class of flavonols have been documented to exert anticancer activity. Q has been shown to be useful in the treatment of non-small cell lung cancer (NSCLC), as demonstrated by in vitro/in vivo studies, due to its antitumor, anti-inflammatory, anti-proliferative, anti-angiogenesis, and apoptotic properties. Some flavonoids (flavone, anthocyanins, and proanthocyanidins) have been demonstrated to be effective in nicotine-induced NSCLC treatment. However, the molecular mechanisms of quercetin derivatives (QDs) in nicotine-induced NSCLC treatment remain unclear. Thus, this review aims to summarize the available literature on the therapeutic effects of QDs in nicotine-induced NSCLC.